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C)ltjdw. Ttds study sought to determine the e&&s of enala- 
prllst on reflex control of sympathetic nerve activity. 
Btzckgwund Angiotensin-convertitiog enzyme inbibitors de- 
crew rwtaBty Is patients with cmgestive hrt failure. Tbeir 
eflicsq appears to be reIs&d importantly to autiadreuergic 
ehts, the tnwlmnh for wbicb has not been determined. 
Beamse bsrorrffexes tonIcsBy inhibit sympathetic outftow, and 
l8smekm m-e blunted in heart fitBore, we bypotbesii that 
these sgents rednce splspstlletlc aivity by augQentlng bsrore- 
tlexes. 
i&Musk. We sssessed lkmretlex control of sympsWc nerve 
sctivlty sud heart rste in pstients with congestive hart fsilnre 
and in contnd subjects before sod after enalaprBat (0.02 mgikg 
body weight lntmvenously). Arterial ImroreRexes wem perturbed 
by bslns fidk&Mb of sodium &roprusside and pkyleph- 
IiW.cardiepnlmonwrbSlW&Xt!SWe~prtorbedbylowwbOdy 
IiegMlW pressw and bertddowu tilt. Muscle sympathetic nerve 
sctlvity wss recorded by q icroueurograpby. 
Congestive heart failure is one of the leading causes of 
morbidity and mortality in the United States today. Although 
several ckses of drugs have been shown to exert beneficial 
hemodynamic effects in patients with heart failure, the only 
dass of drugs that has been approved by the Food and thug 
Administration to reduce. mortality in patients with heart 
failure is the angiotensin-converting enzyme inhibitors. The 
reason for this beneficial effect on morn&y still is not clear. 
The hemodynamic effects of long-term administration of these 
agents are modest at best. In the second Vasodilator-Heart 
Fmm the Depanment of kdicine (cardidogy), Uoiwtity Haspitak of 
cteveld case Weatem Rewve university and Department of veteran.5 
Ahha h4ediml Center, CTkdad, Ohio. Thir work was supported by hinds from 
the Medical Rexarc Se&e of the Dpartmeot of Veterans Main, Washing- 
ton, D.C; by Grant HL MSM Finn the National Heart, Lung, and Blood 
laahte, Natkmaf iilstitutes of Health. Fietks%, Mmyfaad; and by a bkdii 
School Grant from Merck Hyan Eealth Div+!oq West Point, t’etmsyfvania. 
L$.~-~ismeteEipiwt.~ta~Iove~a~Awvdfromtbe 
DepamneadVetermoA5irs.Dr.KinogawaisthereeipientdaResearch 
Fek+&@AwdtmmtheAwicanHeart,kociaticm,NortheastObio 
bhk E. DibnwDunlap, Medical Re- 
bte&calcentcr,lo7olEaal~ 
- 
Resuk Eoslaprilat ,wcreased systolii blood pressure in pa- 
tients wit beart failure and control subjec& Sympathetic nerve 
activity increased in ccntrol subjects but decreased in patients 
with beart failure after enalaprilat despite reductions in central 
venous pressure in this qmp. Baroro&x control of sympathetic 
nerve activity was unchaqed by enalaprilat in control subjects. IO 
patients with beart faiture, both arterial and cardiopulmonary 
bsrore6ex control of sympathetic nerve activity was enhanced by 
enalapriht. Baroretlex control of heart rate was unchged by 
enalapriht in either group. 
Conclusions. Enalaprilat augments botb arterial and cardio- 
pulmonq baroreftex coutrol of sympathetic activity in heart 
failure. The-se augmented inbiBitory Moences are associate4l wttb 
a reduction in sympatbeGc outBow and may contri~te to the 
beneficial etfects of angiotensin-converting enzyme inhibitors in 
heart failure. 
(JAm Gdl &rdid 19%;27:3SS-64) 
Failure Veterans Affairs Cooperative Study Group trial 
(VHeF’I-II) (I), the vasodilator combination hydralazine and 
isosorbide dinitrate exerted a greater benefit on symptoms and 
e::ercise capacity than the converting enzyme inhibitor enala- 
pril, but enalapril reduced mortality to a greater degree. This 
suggests that mechanisms other than (or in addition to) 
vasodilating eflects are important in reducing mortality. 
Neurohumoral excitation is a hallmark of congestive heart 
failure, manifested by elevations in sympathetic nerve actihity 
(2), plasma norepinephrine (3) and plasma renin activity (45). 
The degree of neurohumoral excitation, as measured by circu- 
lating norepinephrine, is directly proportional to mortality (6). 
Angiotensin-converting enzyme inhibitors have sympathoin- 
hibitory effects in patients with heart failure characterized by 
reductions in circulating noreninephrine levels (7) (or blunting 
of the expected rise in nore@ephrine over time IS]), which 
may bc important in their beneticial effects in heart failure (8). 
The mechanism of the sympathoinhibitory effects of 
angiotensin-converting enzyme inhibitors has not been eluci- 
dated. Cody et al. (9) found that captopril admmistration 
resulted in an improved response of systemic vaswlar resia- 
tam and norepinephrine release during tat testing in patients 
with heart failure. This suggests that captopril exerts sahrtq 
effects on card*imonary bimmtlex contd of sympathetic 
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Fable 1. Baseline Characteristics of the Heart Failure Group 
-- 
t’t No. Age (yr) Diagnosis Ejection Fraction (%b NYHA Mediitions 
- 
I 56 Idiopathic 16 111 Captopril. hydralazine, lanoxin, borbide, furoremidc. tnetoba, aspirin, potassium 
chloride 
2 54 Idiopathic 12 II Captopril, lanoxio, warfarin 
3 40 Idiopathic I6 Ill Captopril, hydralazinc, lanodn, fu-idc, hydro&lorothii. mtarsium chknidc, 
warfatin, indomc&acin 
4 49 Mywarditis 8 III l&nopril. law&, hrownide, waffarin, mctd~, potassium chloride 
5 65 Alcoholic I9 Ill Lisinopril, lanoxin, furasemidc, aspirin, isosorbde. rbqhyllire 
6 32 Idiopathic 24 III Captopiil. lanodh fwwmi&, warfarin 
7 62 Idiopathic I3 Ill Captopril, hydralazine, fwosemidc, lanolin, warfarin 
8 42 Miopathii Ill II Usiwpril. lanmin, fu-ide, warfarm. pot&urn chloride 
9 54 Idiopathic 39 II Usinopril, Is&w fwoscmidc, watfarin. buspirow rrtralinc, ranitidinc 
IO 39 Idiopathic 28 III ISqril, lanoxin, bxxbidc. hydmchb&iidc. warfarin 
NYHA = New York Heart Aswciation functional class. 
outflow. Because arterial and cardiopulmonary baroreflexes 
normally exert tonic restraint over sympathetic outtlow, and 
this restraint is diminished in heart failure (lo-12), rve iested 
the hypothesis that the angiotensinconverting enzyme inhibi- 
tor enalaprilat acutely augments both arterial and cardiopul- 
monary baroreflex control of directly meastired sympathetic 
nerve activity in patients with heart failure. 
thetic efferent activity was confirmed by the presence of 
pu&synchronous activity during diastole, its relation to respi- 
ratory activity, its unresponsiveness to arousal stimuli as well as 
an increase in nerve activity in response to nitroprusside- 
induced hypotension. A catheter was placed in the ir.tratho- 
racic cavity through the bmchmcephalic vein for meastilzmer,: 
of central venous pressure and administration of drugs. Beat to 
beat arterial pressure was measured by photoplethysmography 
Methods 
with a Finapress device (Ohmeda). 
Protcd. After instrumentation, subjects rested in the su- 
We studied 10 male patients with heart failure in New York pine position for 10 min. Arteriai barorellex stimulation was 
Heart Association functional classes II and III and 8 age- perfomed by sequential challenges with sodium nitroprusside 
matched control subjects. All patients had been admitted to and phenylephrine intravenously, administered at the nadir of 
the hospital previously for congestive heart failure but were the nitroprussi&-induced hypotension. Doses of each drug 
studied at least 3 months after their most recent exacerbation. were adjusted to provide a 1@ to 20-mm Hg change in arterial 
The characteristics of the patients with heart failure are shown pressure below and above bas&ne. llms, a M to &l-mm Hg 
in Table 1. All patients were taking angiotensin-converting range of arterial pressure was used to calculate arterial barore+ 
enzyme inhibitors, digoxin and diuretic drue (specify medi- flex control of heart rate and muscle sympathetic nerve activity 
cations are shown in Table 1 for each patient). All medications (15). 
were withdrawn for -5 half-lives before the study, including Carditi-&uopary barorellex provocation was performed by 
digoxin. The last dose of diuretic drugs was administered the applying lower body negative pressure to -15 mm Hg Data 
day before the study. All study subjects were asked to refrain were collected during the secorid minute of the stimulus Af’ter 
from drinking ca@einated beverages on the day of the study. a rest period to aIlow restoration of baseIine coodi 
The study protocol was approved by the Institutional Review head&own tilt at lo” was initiated. Data were collected during 
Board of Case Western Reserve University, and all subjects the second rrinute of.hzadaown tilt. 
gave written informed consent before participation in the We then administered enalapG4 0.02 mg& body weight 
StUdy. intraveoously.over5nin.adose~tissiightly~thanthe 
Mtx+sarements. Subjects were. brought to the laboratory recommendedtreatment&6eofl.2Smgfora7O-kgpatieot. 
after a light morning meal. Elernnmrdiographic leads were AfteralO-minrestperiod,tbepreenalapriiatpmtocolwas 
attached, and subjects were instructed to Iie supine in a lower rcpeat~L~arteriaIbaroreflextesthrgand~ 
body negative-pressure chamber that was comtmcted with a, monarybaro&expmvocationwitbIowerbodynegativepre+ 
hinged panel to alh5v ac4zss to the right leg. Muscle sympa- sureand-tilt. 
thetic nerve activity was reco&d using a microelectmde in the werecoIhedandstoredontape(TEAc 
right pefoneal nerve, as has been described pwiously by our posthoc.mestweddatawere~. 
group (13) and others (14). Brie& hanscutaneous mapping backanddigi&dat5OOHz/chaimelusiqanamdog-to-d&d 
was perfomxd aver the peroneal newe as it emerges fmm the 
~h~~~~ 
waainsertedintotheperomzalne 
(NeneTratGcAaslyzer,~ 
t#ioenghIee*hfiltawk,reEtifiedBnd 
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Tahfe 2. Baseline Variables in Heart Failure and Control Groups 
Hern Failure Group 
(mean z SE) 
Heart rate (beaWmia) l-f”4 
Systolic BP (mm Hg) 13455 
Diastolic BP (mm Hg) 7923 
Mean arterial pressure (mm Hg) 97 2 2 
Central ve.nws pressure (mm Hg) 8.3 2 1.1 
Muscle sympathetic nerve activily 62.8 f 6.4 
(bursts/lGU beats) 
Control Group 
(mean F SE) 
67 2 3 
135 i 5 
65 2 3 
MI+? 
2.7 _c 3.3 
37.3 i 4.7 
p Value 
0.0x 
0.93 
0.004 
0.01 
O.M)I 
0.007 
BP = blood presssure. 
control groups, nerve activity was computed as bursts/l00 heart 
beats (I&14,16). 
Arterial baroreflex control of heart rate was calculated from 
the slope of the linear regression relating peak systolic pressure 
to the following RR interval (17). Because muscle sympathetic 
nerve activity is correlated most closely to diastolic blood 
pressure of the previous cardiac cycle (18), arterial baroreflex 
control of sympathetic nerve activity was determined from the 
regression relating diastolic pressure to muscle sympathetic 
nerve activity. Values for muscle sympathetic nerve activity 
(burst amplitude times burst incidence) were determined for 
consecutive bins of diastolic pressure (bin width 3 to 5 mm Hg) 
obtained during the pressure increase from the nadir of 
hypotension. Cardiopulmonary baroreflex controi of sympa- 
thetic nerve activity was determined by calculating change in 
nerve activity from the I-min baseline period preceding each 
intervention (either lower body negative pressure or head- 
down tilt) to the second minute during the intervention. To 
account for different starting values between groups, percent 
change in nerve activity was compared (14). Absolute changes 
rdsc are presented. 
diogram, muscle sympathetic nerve activity and central venous 
pressure to sequential bolujes of nitroprusside and phenyleph- 
rine in one subject. Clearly evident is the increase in sympa- 
thetic nerve activity and concomitant RR interval shortening 
associated with the fall in arterial pressure, Mowed by the 
sympathoinhibitory response and RR interval prolongation 
accompanying the rise in pre<sure. Centra; venous pressure 
remained relatively constant during the changes in pressure. In 
control subjects, nitroprusside, 50 to 200 a, followed by 
phenylephrine, 75 to 250 pg intravenously, was administered to 
produce sweeps of systolic pressure of 28 t 4 mm Hg. In heart 
failure, these doses were 50 to 300 pg of nitroprusside and 125 
to 350 pg of phenylephrine to produce pressure changes of 
30 ir 3 mm Hg. After enalaprila:, the same doses were used, 
resulting in pressure changes of 31 Z 4 mm Hg in control 
subjects and 32 + 2 mm IIg in patients with heart failure (both 
p > 0.5, before vs. after enalaprilat). 
Before enalaprilat, arterial baroreflex control of sympa- 
thetic nerve activity was similar in the heart failure group 
(6.1 2 0.7 bursts/mm Hg) and m control subjects (6.5 -C 0.6 
bursts/mm Hg, p = 0.72) (Fig. 2). This result contrasts with 
The SM System for Windows 3.10, release 6.08, wds used 
for all data analysis. Two-way analysis of variance was used to 
test the effects of group (control vs. heart failure) and treat- 
ment (before vs. after enalaprilat). Individual variables were 
compared within groups by paired two-tailed I tests (before vs. 
after enalaprilat) and between groups by unpaired t tests 
(two-tailed). Das were tested for normality (Shapiro-W& 
statistic) and analyzed by nonparametric tests when found to 
be nonnormal. A p value CO.05 was considered statistically 
sigttikmt. Results are expressed as mean value + SE. 
Qure 1. Record frcrll one subject during sequential nitroprusside 
and phenylephrine admmistration. Note the increase in muscle sym 
pathetic nerve activity (KSNA) during nitroprusside-induced hypoten- 
sion followed by the decrease in sympathetic nerve activity during 
phenylephrine-;sduczl increase in arterial b!ood pressure (BP). Co 
tral venous pressure (O’P) remains constant throughout the record- 
ing. Arterial barorefiex gain was computed during the rise in blood 
pressure from the niiroprusside-induced nadir. Nitroprusside was 
given just before the slrip shown below. ECG = electrocardiigram. 
&?SUltS 
Baseline respoases. Baseline variat’es of the heart faiiuie 
and control groups are shown in Table 2. As expected, heart 
rate was increased in patients with heart failure compared with 
that in control subjects. Mean arterial pressure was also slightly 
higher in the heart failure group than in control subjects 
buse of a higher diitolic blood pressure. Rest sympathetic 
~~~~~~~e~t~~~n~~~ 
fahlre, as has been reported previously (2). 
Fii 1 shows nspoases of arterial pressure, electrocar- 
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I PO%! Enalaprilat l 
cuwdHF Gmtrd HF 
Figure 2 Effect of enalaprilat on ;rterial baroretlexes. Left, Arterial 
baroreflex control of heart rate. Rig&, Arterial baroretlex control of 
muszle sympathetic nerve activity (MSNA). After enalaprilat, there 
was a significant increase in baroreflex control of muscle sympathetic 
nene activity in the heart failure group (HF) only. There was no 
change in baroreflex control of heart rate in either group after 
enalaprilat. bpm = bcats/min; U = Burst amplitude X Bursts/l00 
heartbeats. ‘p < 0.05, before versus after enalaprilat. Results are mean 
value 2 SE. 
arterial baroreflex control of heart rate, which was attenuated 
signihcantly in the heart failure group (heart failure group 
5.3 2 0.6 beats/mm per mm Hg vs. control group 10.8 5 
0.9 beats/min per mm Hg, p < O.OfW). 
Lower body negative pressure reduced central venous pres- 
sure by 3.5 2 0.5 mm Hg in control subjects and by 3.4 5 
0.8 mm Hg in patients with heart failure. These changes were 
accompanied by a 36 -t 6% (12.3 2 1.3 absolute U) increase in 
muscle sympathetic nerve activity in control subjects but only 
18 2 6% (95 f 2.0 absolute U) in patients with heart failure 
(p CC 0.05). Headdown tilt increased central venous pressure 
by 1.3 +- 0.2 mm Hg in control subjects and by 0.7 2 0.4 mm Hg 
in patients with heart fake. These were accompanied by 
insignificant changes in muscle sympathetic nerve activity in 
both groups. 
Efkts nf enafaprflat. Enalaprilat treatment resulted in 
small effects on hemodynamic variables. Systolic blood pres- 
sure was reduced in both groups (by 6.5 t 2.0 mm Hg in 
control subjects, by 5.8 2 1.7 mm Hg in patients with heart 
failure, both p < 0.02). Diastolic pressure did not change 
significantly in either group (+2.9 It 1.4 mm Hg in control 
subjects, + 1.0 -C 1.2 mm Hg in patients with heart failure, both 
p Z 0.05). Figure 3 shows additional changes in baseline 
variables in the heart failure and control groups after enala- 
p&t. Mean arterial pressure and central venous pressure 
were unchanged in control snbjects after enalaprilat treatment, 
and there were small increases in heart rate and muscle 
syttpnihetic nerve activity. None of the changes in control 
subjects were slatistieatly sign&ant In the heart failure group, 
responses of heart rate and mu&e sympathetic nerve activity 
to enalaprilat were diieetionaliy opposite to those of control 
suhjec@ consisting of rekticms in both measurements. This 
reaehed statistical rjig&am for musde sympathetic nerve 
activity @ = 0.04, before vs. after enaiaprilat) and occurred 
despkeasignificant~reduaionincentrafvenons prasure in 
heartfaihrreandatrettdtowardredncedmeanaiterialpres- 
sure. 
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Fiire 3. Changes in baseline v;:;abies after enalaprilat 0.02 mglrg 
intravenously. Sympathetic nerve activigdecreascl in the heart failure 
group despite a reduction in central venous pressure (CVP [mm Hg]) 
that was not present in control subjects. HR = heart rate (heatsimin): 
MAP = mean arterial pressure (mm Hg); MSNA = muscle ynpa- 
thetic nerve activity (burstsW0 heartbeats). ‘p c It.05 before vcrw 
after enalaprilat. heart failure group. Results are mean value 5 SE. 
Figure 2 shows the effects of enalaprilat on arterial barore- 
flexes. In control subjects. arterial barorefiex control of both 
bear? rate and sympathetic nerve activity I.VZ unchanged after 
enalaprilat. In patients with heart failure, arterial baroreflex 
control of heart rate also was unchanged after enalaprilat. 
However, arterial baroreflex control of sympathetic nerve 
activity was augmented signikantty after cnalaprilat in pa- 
tients with heart failure. 
The effect of enataprilat on cardiopulmonary baroreflex 
control of sympathetic nerve activity was different in the two 
groups, and responses are depicted in Figure 4. In control 
subje& the increase in muscle sympathe!ic nerve activity with 
lower body negative pressure was unchanged by enalaprilat 
(-1 ? 4%). In contrast, patients with bean failure exhibited 
signihcantty augmented cardiilmonary baroreflex gain of 
muscle sympathetic nerve activity as measure3 by an increase 
of 8.3 + 3.6% (p < 0.05, before vs. after endapritat). Head- 
down tilt had essentially no effect on muscie sympathetic nerve 
activity, and responses of muscle sympathetic nt:ne activity to 
head-down tiit were unchanged in both groups after enalapri- 
lat. Dms, angiotemin-converting enzyme inhibitors increased 
the gain in reqmnse to un.loading of cardiiuhnonaty barore- 
flexes in patients with heart failure. 
DiSCUSSioa 
Treatment with angiotensinconverting enzyme inhibitors 
has heen shown ta bhmt the sympatttoexcitation that is a 
hafhnark of wnge&ve heart failure. The mechanism respon- 
sible for this ~thoinhibm3ty effect has not been ekidated. 
BetL&sedii~~lhataannauyaetivatetalherthaa 
iuhibitqmpathetkout&warenotasef~as~e 
~e~g~~~~~~~~ 
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Fire 4. Effect of enalaprilat on cardiopulmonary haro:ctlexes. Base 
line cardiqulmonary baroretlex control of muscle sympathetic nerve 
activity (MSNA) was reduced in patients with heart failure (HF) 
compared rvlth that in control subjects. After enalaprilat, cardiopul- 
monary baroreflex control of muscle sympathetic nerve activity was 
augment-d in patients wit!: kc ::; f;l!;i;c only. #p < 0.05. patients with 
heart failure versus control sJhjects. ‘p < 0.05, befnrc versus after 
enalaprilat. Results are mean value _C SE. 
failure (I), this effect appears to be important in improving 
outcome in these patients. To our knowledge, our study 
demonstrates for the first time that short-term treatment with 
enalaprilat augments barrjreflcxcontrol of sympathetic outflow 
in patients. 
Control of sympathetic outflow. Both arterial and cardio- 
pulmonary haroreflexes normally exert tonic restraint over 
sympathetic outflow. Experiments in both humans and animals 
have revealed marked impairment of barorcflexes in heart 
failure. including reduced arterial baroreflex control of heart 
rat< (19), decreased sensitivity of arterial baroreccptor affer- 
ents (12,21)), and decreased cardi.>puimonary baroreflex con- 
trol of forearm vascular resistance (21,22). 
Previous studies from our laboratory and elsewhere have 
demonstrated that cardiopulmonary haroreflex control of fore- 
arm vascular resistance is attenuated in patients with heart 
failure (21.22). To our knowledge, the current study is the first 
in patients with heart failure to record muscle sympathetic 
nerve activity directly in response to lower body negative 
pressure and confirms that cardiopulmonary baroreflcx control 
of sympathetic outflow is attenuated in heart failure, rather 
than effects mediated by other mechanisms, such as changes in 
end-organ responsiveness or norepinephrine kinetics. 
Distension of the atria and ventricles normally activates 
vagdi afferent fibers and leads to a reduction in sympathetic 
outflow. Despite (llr because of) chronic increases in cardiac 
filling pressure, these normal sympathoinhibitory responses 
are blunted in heart farlure (11!.2?,23). Decreased function of 
these reflexes would be expected to lead to chronic increases in 
Sj’filpdtktk cwtflmv. as were found in our study a% well as in 
prt!!ious studies in patient> with heart failure (2), 
Ferguson et al. (24) studied arterial baroretlex function in 
patients with heart failure using inf&ons of phemkphrine 
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and nitroprusside to stimulate barorcflexcs. They intcrpretcd 
their resilts to suggest that arterial baroreflex control of 
sympathetic activity was blunted in patients with heart failure. 
However, as pointed out previously (25). their study could not 
differentiate between activation of arterial and eardiopdmo- 
naty barorcflexcs. The technique used in the current study 
resulted in changes in arterial pressure in the absence of 
significant changes in central venous pressure, thus isolating 
the two sets of reflexes. Our data from the current study show 
that the major defect is in cardiopulmonary baroreflex and not 
in arterial barorcflex control of sympathetic activity. These 
data are in agreement with previous animal studies from both 
our laboratory (IO) and others (26). 
The effects of angiotensin-converting enzyme inhibitors on 
circulating norcpinephrine levels in patients with heart failure 
have been found to vary, with some studies showing no change 
(27-29), some showing a decrease (30-33) and some showing 
the lack of an expected increase over time with angiotensin- 
eonvcrtingenzyme inhibitortreatment( Becauscangiotcnsin- 
converting enzyme inhibitors decrease arterial and cardiac 
filling pressures, this deactivation of baroretlexes would nor- 
mally be expected to result in increases in heart rate and 
sympathetic outflow. The lack of an increase in norepinephrine 
after angiotensin-eonverting enzyme inhibitors--a result eon- 
sistent in all these studies-is consistent with a sympathoin- 
hibitory effect of angiotensin-eonverting enzyme inhibitors in 
heart failure. 
Angiotensin II facilitates norepinephrine reicase from sym- 
pathetic verve endings (34). Blocking these eff:%s couhl 
account in part for some of the sympathoinhibitory aetion 01 
angiotensin-converting enzyme inhibitors. However, this does 
not explain our findings, as we measured nerve activity directly. 
Cody et al. (9) found that capiopril significantly enhanced 
changes in systemic vascular resistance and plasma norepi- 
nephrine (but not heart rate) in response to tilt. Our data arc 
consistent with those observations and extend these previous 
findings by showing that angiotensin-converting enzyme inhib- 
itors decrease sympathetic nerve activity measured directly in 
patients with heart failure, despite effects on hemodynamic 
variables that tend to counter this effect. Because this is 
accompanied by augmented barorcflex control of sympathetic 
outflow, it is possible that improvement in baroreflexes could 
be thL mechanism by which angiotensin-eonverting enzyme 
inhibnor treatment leads to sympathoinhibitory effects. 
Mrrhanim of 8ction of oqio~sin-roovertiag enzyme 
inhibitors on barnrefkxw. We studied the effect of enalapnlat 
on baroreflex control of sympathetic nerve activity as well as 
he-art r:tte. Arterial barorefiex control of heart rate was *e- 
duced in patients with heart failure but was unchanged after 
enalaprilat. This suggests that the site of a&n was piobabiy 
not sensitization of baroreeeptor afferents because this would 
have bcen expected to result in enhanced baroretlex eontroi pf 
both sympathetic nerve activity and heart rate. This is consis- 
tent with animai studies that show that angiotensin if tends to 
hxeasc awotid sin* bamreeepttn smshivity (35). Therefore, 
Mucking production of angiotcnsin II wou~ be e~pccled to 
JACC Vol. 27, No. 2 
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decrease, not increaw, sensitivity c” abrent pathways, so 
irnprovemrnts in baroreflexes cannot be explained by this 
mechanism. 
In experiments in cats, Schmid et al. (35) found that graded 
doses of angiotensin 11 caused a smaller change in lumbar 
sympathetic nerve activity per change in aortic nerve activity 
than either phenylephrine or vasopressin, indicative of central 
depression rf the baroreceptor-sympathetic reflex. Further, 
i!ayashi et al (36) found that central administration of angio- 
tensin II inhibited sympathoinhibitory responses to aortic 
depressor nerve stimulation in rats. These findings indicate 
that angiotensin 11 acts centrally to attenuate baroreflex con- 
trol of sympathetic activity. Data from our study are consistent 
with a central site of action on baroreflexes. 
Dorward and Rudd (37) infused an angiotensin II antago- 
nist centrally in cats and were unable to demonstrate signifi- 
cant effects on heart rate or renal sympathetic nerve activity. 
From this they concluded that angiotensin 11 does not tonically 
modulate parasympathetic or sympathetic outflow. Our data 
showing a lack of effect of enalaprilat on baroreflexes in 
control subjects are consistent with the study by Forward and 
Rudd and support the concept that angiotensin 11 does not 
tonically regulate baroreflexes in normal subjects. This cnn- 
tiasts with the situation in patients with heart failure, when 
angiotensin 11 does exert significant tonic inhibitory effect as 
evidenced by augmented baroreflexes after enalaprilat. 
Our results in patients with heart failure have marked 
similarities to findings in rats from Kumagai et al. (38). They 
found no effect of captopril on baroredexes in nonnotcrsive 
rats. In contrast, spontaneously hypertensive rats showed en- 
hanced baroreflex control of renal sympathetic nerve activity 
after captopril but no effect on bamreflex control of heart rate. 
Therefore, tonic effects of angiotensin II on baroreflexes 
appear to become important only in the presence of activation 
of the renin-angiotensin system, for example, in heart fadure 
or hypertension. 
Ostetziel et al. (39) studied the effects of a single oral dose 
of captopril, 25 mg, on RR interval changes induced by carotid 
sinus baroreceptor provocation with neck suction. They found 
that captopril increased arterial bamreflex control of RR 
interval in patients with heart failure. Vogt et al. (40) also 
found augmented RR interval responses to neck suction 24 h 
after a single oral dose of ramipril, 5 mg. Although the 
differences between these previous studies and ours cannot be 
ascertained for certain, one possible explanation could bc that 
in bofh of those studies, patients were maintained on digoxin. 
We withdrew patients from all drugs for our study and found 
no effect of enalaprilat on heart rate responses. It is known that 
digoxin exerts important vagomimetic actions, even in patienti 
with heart faiLe (41). Therefore, it is possible that angiotensin- 
converting enzyme inhibitors can potentiate the vagal effects of 
digoxin in heart failure but do not have direct effects on heart 
rate themselves. 
Alternatively, both of the previous studies used heart rate 
responm to sumined neck suchon to examine baroreflex 
elm wherea we analyzed bamreflex mtrol through dy- 
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namic pressure ramps induced bv sequential nitropru&de/ 
phenylephrine challenge. It is possible that these differences in 
techniques could account for observed differences in responses 
of baroreflex control of heart rate. Other medical therapy used 
for treatment of heart failure may also exert significant effects 
on baroreflexes. These have been reviewed previously (42). 
Study lJmdtatJo~a In a study examining the ahort- and 
long-term effects of captopril, Cody et al. (9) found that the 
response of systemic vascular resistance to tilt was less pm 
nounced during long-term therapy with captopril than after 
short-term administration. Because our study focused on acute 
effects of an angiotensin-converting enzyme inht%tor, we do 
not know whether these results would be maintained during 
long-term treatment. However, because the increase in norepi- 
nephrine was improved after both short- and long-term capto- 
pril treatment in the study by Cody et al. (9), we speculate that 
improvement in baroreflex control in sympathetic outRow 
mi$t account for these changes and thus also be maintained 
dunng long-term treatment. 
In addition to inhibiting conversion of angiotensin 1 to 
angiotensin 11, angiotemin-cr nverting enzyme inhibitors b&k 
the actions of kininase 11, thus increasing kxal concentrations 
of bradykinin. Whereas central administration of angiotensin 
11 (which is decreased by angiotensin-converting enzyme in- 
hibitors) blunts baroreflexes, central administration of brady- 
kinin (which is inL?eased by angiotensin-convcrting en.tyme 
inhibitors) augments baroreflexes (43). Therefore, either 
mechanism could account for the effects on baroreflexes that 
we demonstrated, and the relative contribution of each can be 
elucidated only with further study. 
Coocl~~loaa The presnt stu& demonstrates that cardio- 
pulmonary baroreflex control of sympathetic rrerve activity is 
biun:ed, but beeline arterial baroreflex control of sympathetic 
nerve activity is preserved in patients with heart failure. 
Short-term treatment with enalapdat augments both arterial 
and cardiopulmonary reflex control of sympathetic activity in 
patients with heart failure. This improvement in barorellexes 
leads to a reduction in sympathetic activity. We speculate that 
these effects of angiotensin-converting enzyme inhibitors are 
important for tbeir beneficial effects in patients with heart 
failure. 
WE gratefully x!.nwiedge the help af the Clinical Raea rh renter of fJniw- 
sity Hqitab of Ikvchnd f.x assisting witb this study. as well as dae tahnial 
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